KR950703528A - 프로스타글란딘 e₁유연체 - Google Patents
프로스타글란딘 e₁유연체 Download PDFInfo
- Publication number
- KR950703528A KR950703528A KR1019950701486A KR19950701486A KR950703528A KR 950703528 A KR950703528 A KR 950703528A KR 1019950701486 A KR1019950701486 A KR 1019950701486A KR 19950701486 A KR19950701486 A KR 19950701486A KR 950703528 A KR950703528 A KR 950703528A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- pharmaceutically acceptable
- formula
- acceptable salt
- prostaglandin
- Prior art date
Links
- 150000003180 prostaglandins Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003836 peripheral circulation Effects 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
식
(식중, R1은 수소원자 또는 C1∼C6알킬기를 나타내고, X는 산소원자이며, R2는또는를 나타내던가, 또는 X는 유환원자이며 R2 를 나타낸다)로 표시되는 프로스타글란딘 E1유연체. 본 발명 화합물은 혈소판 응집억제작용을 가지고 있으며, 말초순환장애를 비롯한 각종 혈전성 질환의 처치에 유용하다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (7)
- 식(식중, R1은 수소원자 또는 C1∼C6알킬기를 나타내고, X는 산소원자이며, R2는또는를 나타내던가, 또는 X는 유환원자이며 R2 를 나타낸다)로 표시되는 프로스타글란딘 E1유연체 및 그의 염.
- R1이 수소원자 또는 C1∼C4알킬기인 청구항1 기재의 화합물.
- 청구범위 제1항 기재의 식(I) 화합물 또는 제약학적으로 허용되는 그의 염을 함유하는 약제.
- 청구범위 제1항의 기재의 식(I) 화합물 또는 제약학적으로 허용되는 그의 염을 함유하는 혈소판 응집억제제.
- 청구범위 제1항의 기재의 식(I) 화합물 또는 제약학적으로 허용되는 그의 염 및 제약학적으로 허용되는 첨가제로 된 약학적 조성물.
- 청구범위 제1항의 기재의 식(I) 화합물 또는 제약학적으로 허용되는 그의 염의 유효량을 포유동물에 투여하는 것으로 되는 포유동물의 신장질환 또는 순환기질환의 처치방법.
- 청구범위 제1항의 기재의 식(I) 화합물 또는 제약학적으로 허용되는 그의 염의 질병의 처치를 위한 사용.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP282088/1992 | 1992-10-21 | ||
JP28208892 | 1992-10-21 | ||
PCT/JP1993/001510 WO1994008961A1 (en) | 1992-10-21 | 1993-10-20 | Prostaglandin e1 analog |
Publications (1)
Publication Number | Publication Date |
---|---|
KR950703528A true KR950703528A (ko) | 1995-09-20 |
Family
ID=17647970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950701486A KR950703528A (ko) | 1992-10-21 | 1993-10-20 | 프로스타글란딘 e₁유연체 |
Country Status (6)
Country | Link |
---|---|
US (1) | US5583158A (ko) |
EP (1) | EP0666257A1 (ko) |
KR (1) | KR950703528A (ko) |
AU (1) | AU669950B2 (ko) |
CA (1) | CA2147461A1 (ko) |
WO (1) | WO1994008961A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU657953B2 (en) * | 1991-04-22 | 1995-03-30 | Fumie Sato | Prostaglandin E1 analogue |
US7018627B1 (en) | 1995-06-07 | 2006-03-28 | Icos Corporation | Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof |
WO2018220730A1 (ja) * | 2017-05-31 | 2018-12-06 | 国立大学法人東北大学 | Pge1コアブロック誘導体およびその製造方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4029681A (en) * | 1976-02-13 | 1977-06-14 | The Upjohn Company | 13,14-Didehydro-PG analogs |
US4061670A (en) * | 1976-07-19 | 1977-12-06 | American Cyanamid Company | 15-Deoxy-16-hydroxy-16-vinyl and cyclopropyl substituted prostanoic acids and congeners |
AU3437478A (en) * | 1977-03-30 | 1979-09-27 | American Cyanamid Co | Prostanoic acids and congeners |
US4131738A (en) * | 1977-07-05 | 1978-12-26 | The Upjohn Company | 6-Hydroxy-PGE1 compounds |
GB2006186A (en) * | 1977-08-29 | 1979-05-02 | American Cyanamid Co | 15-Deoxy-16-substituted prostanoic acids |
AU657953B2 (en) * | 1991-04-22 | 1995-03-30 | Fumie Sato | Prostaglandin E1 analogue |
JPH05117230A (ja) * | 1991-04-22 | 1993-05-14 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体 |
-
1990
- 1990-11-20 CA CA002147461A patent/CA2147461A1/en not_active Abandoned
-
1993
- 1993-10-20 AU AU52856/93A patent/AU669950B2/en not_active Ceased
- 1993-10-20 US US08/416,871 patent/US5583158A/en not_active Expired - Fee Related
- 1993-10-20 WO PCT/JP1993/001510 patent/WO1994008961A1/ja not_active Application Discontinuation
- 1993-10-20 EP EP93923031A patent/EP0666257A1/en not_active Withdrawn
- 1993-10-20 KR KR1019950701486A patent/KR950703528A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU5285693A (en) | 1994-05-09 |
EP0666257A1 (en) | 1995-08-09 |
US5583158A (en) | 1996-12-10 |
AU669950B2 (en) | 1996-06-27 |
WO1994008961A1 (en) | 1994-04-28 |
CA2147461A1 (en) | 1994-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920700200A (ko) | 19-노르-비타민 d 화합물 | |
KR890011592A (ko) | 기관내 허혈병의 치료용 조성물 | |
KR950005308A (ko) | 직장투여용 조성물 | |
KR920002144A (ko) | 아연 l-카르노신 염 또는 이의 착화합물을 유효성분으로 함유하는 염증성 장질환 예방 및 치료제 | |
KR950703527A (ko) | 프로스타글란딘 유도체 | |
KR900006318A (ko) | 피페리디닐 벤즈이미다졸 | |
KR950010892A (ko) | 자궁 섬유증 억제 방법 | |
ES2155093T3 (es) | Nuevos inhibidores de la uridina fosforilasa (urdpasa) y de la dihidrouracil deshidrogenasa (dhudasa). | |
KR940005274A (ko) | 쇼그렌(Sjoegren)증후군 치료제 | |
RU94044454A (ru) | Ингибитор аутоимунных заболеваний | |
KR950016726A (ko) | 기능부전성 자궁 출혈을 억제하는 방법 | |
KR950016727A (ko) | 트롬보모듈린 발현을 증가시키는 방법 | |
KR950010889A (ko) | 혈관형성 및 혈관형성성 질병을 억제하는 방법 | |
KR890011596A (ko) | 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도 | |
KR950010891A (ko) | 내성 종양을 치료하는 방법 | |
KR900001643A (ko) | 항균제 | |
KR950702554A (ko) | 소염제로서 유용한 2-헤테로시클릭-5-히드록시-1,3-피리미딘 (2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents) | |
KR900016135A (ko) | 피부 및 점막-상피의 질환 치료용 4-퀴놀린 카복실산 유도체 | |
KR910004191A (ko) | 신질환치료제 | |
KR950016760A (ko) | 치질 치료제 | |
RU94045271A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера | |
KR950701638A (ko) | 푸린 동족체의 항비루스성 포스폰산 유도체(Antiviral phosphonic acid derivatives of purine analogues) | |
KR890008136A (ko) | 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체 | |
KR950703528A (ko) | 프로스타글란딘 e₁유연체 | |
KR910018348A (ko) | 술포닐아미노치환 비시클로환계 히드록삼산 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |